1. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992; 71(4):197–205.
2. Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988; 84(4):654–60.
Article
3. Albright F, Reifenstein EC. The parathyroid glands and metabolic bone disease. selected studies. Baltimore: Williams & Wilkins Co.;1948; p.xxvi–p.393.
4. Mizrachi A, Gilat H, Bachar G, Feinmesser R, Shpitzer T. Elevated parathyroid hormone levels after parathyroidectomy for primary hyperparathyroidism. Head Neck. 2009; 31(11):1456–60.
Article
5. Mittendorf EA, McHenry CR. Persistent parathyroid hormone elevation following curative parathyroidectomy for primary hyperparathyroidism. Arch Otolaryngol Head Neck Surg. 2002; 128(3):275–9.
Article
6. Graal MB, Wolffenbuttel BH. Consequences of long-term hyperparathyroidism. Neth J Med. 1998; 53(1):37–42.
Article
7. Heath DA, Van't Hoff W, Barnes AD, Gray JG. Value of 1-alpha-hydroxy vitamin D3 in treatment of primary hyperparathyroidism before parathyroidectomy. Br Med J. 1979; 1(6161):450–2.
Article
8. Boyle IT, Hodsman ID, Allam BF, Boyce B, McLennan I. 1-alpha-Hydroxyvitamin D3 in the management of primary hyperparathyroidism with bone disease. Calcif Tissue Res. 1977; 22(Suppl:415):
9. Malabu UH, Founda MA. Primary hyperparathyroidism in Saudi Arabia: a review of 46 cases. Med J Malaysia. 2007; 62(5):394–7.
10. Lee IT, Sheu WH, Tu ST, Kuo SW, Pei D. Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. J Bone Miner Metab. 2006; 24(3):255–8.
Article
11. Franca TC, Griz L, Pinho J, Diniz ET, Andrade LD, Lucena CS. et al. Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica. Rev Bras Reumatol. 2011; 51(2):131–7.